BACKGROUND: The association of survival with characteristics of thrice-weekly hemodialysis (HD) treatment, including dose or duration of treatment, has not been completely elucidated, especially in different race and sex categories. STUDY DESIGN: We examined associations of time-averaged and quarterly varying (time-dependent) delivered HD dose and treatment time and 5-year (July 2001-June 2006) survival. SETTING & PARTICIPANTS: 88,153 thrice-weekly-treated HD patients from DaVita dialysis clinics. PREDICTORS: HD treatment dose (single-pool Kt/V) and treatment time. OUTCOMES & OTHER MEASUREMENTS: 5-Year mortality. RESULTS: Thrice-weekly treatment time < 3 hours (but > or = 2.5 hours) per HD session compared with > or = 3.5 hours (but < 5 hours) was associated with increased death risk independent of Kt/V dose. The greatest survival gain of higher HD dose was associated with a Kt/V approaching the 1.6-1.8 range, beyond which survival gain was minimal, nonexistent, or even tended to reverse in African American men and those with 4-5 hours of HD treatment. In non-Hispanic white women, Kt/V > 1.8 continued to show survival advantage trends, especially in time-dependent models. LIMITATIONS: Our results may incorporate uncontrolled confounding. Achieved Kt/V may have different associations than targeted Kt/V. CONCLUSIONS: HD treatment dose and time appear to have different associations with survival in different sex or race groups. Randomized controlled trials may be warranted to examine these associations across different racial and demographic groups. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
BACKGROUND: The association of survival with characteristics of thrice-weekly hemodialysis (HD) treatment, including dose or duration of treatment, has not been completely elucidated, especially in different race and sex categories. STUDY DESIGN: We examined associations of time-averaged and quarterly varying (time-dependent) delivered HD dose and treatment time and 5-year (July 2001-June 2006) survival. SETTING & PARTICIPANTS: 88,153 thrice-weekly-treated HDpatients from DaVita dialysis clinics. PREDICTORS: HD treatment dose (single-pool Kt/V) and treatment time. OUTCOMES & OTHER MEASUREMENTS: 5-Year mortality. RESULTS: Thrice-weekly treatment time < 3 hours (but > or = 2.5 hours) per HD session compared with > or = 3.5 hours (but < 5 hours) was associated with increased death risk independent of Kt/V dose. The greatest survival gain of higher HD dose was associated with a Kt/V approaching the 1.6-1.8 range, beyond which survival gain was minimal, nonexistent, or even tended to reverse in African American men and those with 4-5 hours of HD treatment. In non-Hispanic white women, Kt/V > 1.8 continued to show survival advantage trends, especially in time-dependent models. LIMITATIONS: Our results may incorporate uncontrolled confounding. Achieved Kt/V may have different associations than targeted Kt/V. CONCLUSIONS:HD treatment dose and time appear to have different associations with survival in different sex or race groups. Randomized controlled trials may be warranted to examine these associations across different racial and demographic groups. Copyright 2009 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Authors: C Combe; P Chauveau; M Laville; D Fouque; R Azar; N Cano; B Canaud; H Roth; X Leverve; M Aparicio Journal: Am J Kidney Dis Date: 2001-01 Impact factor: 8.860
Authors: Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2008-07-30 Impact factor: 10.121
Authors: Christian S Shinaberger; Joel D Kopple; Csaba P Kovesdy; Charles J McAllister; David van Wyck; Sander Greenland; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2008-08-13 Impact factor: 8.237
Authors: Christian S Shinaberger; Sander Greenland; Joel D Kopple; David Van Wyck; Rajnish Mehrotra; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: John T Daugirdas; Tom Greene; Thomas A Depner; Nathan W Levin; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2011-04-21 Impact factor: 8.237
Authors: Eduardo Lacson; Jianglin Xu; Rita S Suri; Gihad Nesrallah; Robert Lindsay; Amit X Garg; Keith Lester; Norma Ofsthun; Michael Lazarus; Raymond M Hakim Journal: J Am Soc Nephrol Date: 2012-02-23 Impact factor: 10.121
Authors: Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2010-09-03 Impact factor: 3.754
Authors: Marcelo S Sampaio; Miklos Z Molnar; Csaba P Kovesdy; Rajnish Mehrotra; Istvan Mucsi; John J Sim; Mahesh Krishnan; Allen R Nissenson; Kamyar Kalantar-Zadeh Journal: Clin J Am Soc Nephrol Date: 2011-09-29 Impact factor: 8.237
Authors: Kamyar Kalantar-Zadeh; Elani Streja; Csaba P Kovesdy; Antigone Oreopoulos; Nazanin Noori; Jennie Jing; Allen R Nissenson; Mahesh Krishnan; Joel D Kopple; Rajnish Mehrotra; Stefan D Anker Journal: Mayo Clin Proc Date: 2010-11 Impact factor: 7.616
Authors: Vanessa A Ravel; Miklos Z Molnar; Elani Streja; Jun Chul Kim; Alla Victoroff; Jennie Jing; Debbie Benner; Keith C Norris; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Nutr Date: 2013-05-22 Impact factor: 4.798
Authors: Connie M Rhee; Paungpaga Lertdumrongluk; Elani Streja; Jongha Park; Hamid Moradi; Wei Ling Lau; Keith C Norris; Allen R Nissenson; Alpesh N Amin; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2014-02-15 Impact factor: 3.754